Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC).

Rachel N.  Grisham

Consulting or Advisory Role - Clovis Oncology; GlaxoSmithKline; Mateon Therapeutics; Regeneron

Research Funding - Context Therapeutics (Inst)

Travel, Accommodations, Expenses - EMD Serono

Other Relationship - Aptitude Health; MCM Education; OncLive; Prime Oncology

(OPTIONAL) Uncompensated Relationships - Verastem

Ignace  Vergote

Consulting or Advisory Role - Amgen (Inst); AstraZeneca; Carrick Therapeutics (Inst); Clovis Oncology (Inst); Deciphera (Inst); Elevar Therapeutics; Genmab (Inst); GlaxoSmithKline; Immunogen; Jazz Pharmaceuticals; Mersana; MSD; Novocure; Octimet (Inst); Oncoinvent; Roche; Sotio; Tesaro (Inst); Verastem (Inst); Zentalis

Research Funding - Amgen (Inst); Genmab (Inst); Oncoinvent (Inst); Roche (Inst)

Travel, Accommodations, Expenses - Amgen; AstraZeneca; MSD/Merck; Roche; Tesaro

Susana N.  Banerjee

Honoraria - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Pfizer

Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Carrick Therapeutics (Inst); Clovis Oncology; GenMab; GlaxoSmithKline; Merck; Mersana; MSD Oncology; Roche; Tesaro

Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Nucana

Esther N.  Drill

No Relationships to Disclose

Michel  Fabbro

Honoraria - AstraZeneca

Consulting or Advisory Role - AstraZeneca; Tesaro/GSK (Inst)

Travel, Accommodations, Expenses - Roche

Mansoor Raza  Mirza

Leadership - Karyopharm Therapeutics; Sera Prognostics

Stock and Other Ownership Interests  - Karyopharm Therapeutics; Sera Prognostics

Honoraria - AstraZeneca; Geneos; Genmab/Seattle Genetics; GlaxoSmithKline; Merck; Mersana; Oncology Venture; Roche; Sotio; Takeda; Zai Lab

Consulting or Advisory Role - AstraZeneca; BioCad; Cerulean Pharma; Genmab; GlaxoSmithKline; Karyopharm Therapeutics; Pfizer; Sotio

Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Pfizer (Inst); Tesaro (Inst)

Patents, Royalties, Other Intellectual Property - AstraZeneca (Inst); GlaxoSmithKline (Inst); Pfizer (Inst); Ultimovacs (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Karyopharm Therapeutics; Pfizer; Roche; SeraCare; Tesaro

Other Relationship - European Network of Gynaecological Oncologic Trials; European Society for Gynaecological Oncology; Gynecological Cancer InterGroup

Ignacio  Romero

Consulting or Advisory Role - AstraZeneca Spain; Clovis Oncology; GlaxoSmithKline; Roche

Speakers' Bureau - AstraZeneca; GlaxoSmithKline; PharmaMar; Roche

Research Funding - Roche (Inst)

Travel, Accommodations, Expenses - AstraZeneca Spain; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche

Robert L.  Coleman

Employment - US Oncology

Stock and Other Ownership Interests  - McKesson

Consulting or Advisory Role - Abbvie; Abbvie/Stemcentrx; Agenus; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Genentech/Roche; Genmab; Immunogen; Novocure; Oncolytics; OncoMed; OncoSec; Sotio; Tesaro

Research Funding - Abbott/AbbVie; Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Johnson & Johnson; Merck; OncoMed; Roche/Genentech

Travel, Accommodations, Expenses - Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Clovis Oncology; GOG Foundation; Merck; Research to Practice; Roche/Genentech; Sotio; Vaniam Group

Amit M.  Oza

(OPTIONAL) Uncompensated Relationships - Ozmosis Research

Felix  Hilpert

No Relationships to Disclose

Kathleen N.  Moore

Honoraria - Physicans' Education Resource; Prime Oncology; Research To Practice

Consulting or Advisory Role - Abbvie; Aravive; AstraZeneca (Inst); Eisai; Genentech/Roche; Immunogen; Merck; Mersana (Inst); Myriad Genetics; Pfizer/EMD Serono; TESARO (Inst); Vavotar Life Sciences; VBL Therapeutics

Research Funding - Abbvie/Stemcentrx (Inst); Advaxis (Inst); Agenus (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Forty Seven (Inst); Genentech (Inst); Immunogen (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Novogen (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Stem CentRx (Inst); Takeda (Inst); Tesaro (Inst); Verastem (Inst)

Anneke M.  Westermann

No Relationships to Disclose

Carol  Aghajanian

Consulting or Advisory Role - Abbvie; AstraZeneca/Merck; Eisai; Eisai; Mersana; Repare Therapeutics; Roche; Roche/Genentech

Research Funding - Abbvie (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst)

Giovanni  Scambia

Consulting or Advisory Role - AstraZeneca; Clovis Oncology; PharmaMar; Roche; Tesaro

Speakers' Bureau - Clovis Oncology; MSD

Adam P.  Boyd

Employment - Array BioPharma; Pfizer

Stock and Other Ownership Interests  - Array BioPharma

Travel, Accommodations, Expenses - Array BioPharma

Jean  Cantey-Kiser

Employment - Pharpoint Research

David M.  O'Malley

Consulting or Advisory Role - Abbvie; Agenus; Ambry Genetics; AstraZeneca; Clovis Oncology; Eisai; Elevar Therapeutics; Genelux; Genentech/Roche; GlaxoSmithKline; GOG Foundation; Immunogen; Iovance Biotherapeutics; Janssen Oncology; Leap Therapeutics; Marker Therapeutics; Myriad Genetics; Novartis; Novocure; OncoQuest; Regeneron; Rubius Therapeutics; Rubius Therapeutics; Seagen; Sorrento Therapeutics; Tarveda Therapeutics; Tesaro; Translational Genomics Research Institute

Research Funding - Abbvie (Inst); Abbvie/Stemcentrx (Inst); Agenus (Inst); Ajinomoto (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); Eisai (Inst); Eisai (Inst); EMD Serono (Inst); Ergomed (Inst); Genentech/Roche (Inst); Genmab (Inst); Immunogen (Inst); Immunogen (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Leap Therapeutics (Inst); Merck (Inst); Mersana (Inst); PharmaMar (Inst); Regeneron (Inst); Seagen (Inst); Tesaro (Inst); TRACON Pharma (Inst)

John H.  Farley

Consulting or Advisory Role - Genentech

Speakers' Bureau - Genentech

Nicoletta  Colombo

Honoraria - Amgen; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; mersana; MSD Oncology; Novartis; Pfizer; Pfizer; PharmaMar; Roche/Genentech; Tesaro

Consulting or Advisory Role - AstraZeneca; BioCad; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Pfizer; Pfizer; PharmaMar; Roche/Genentech; Tesaro

Bradley J.  Monk

Leadership - US Oncology

Honoraria - Abbvie; Advaxis; Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Asymmetric Therapeutics; Boston Biomedical; ChemoID; Clovis Oncology; Deciphera; Eisai; Elevar Therapeutics; Geistlich Pharma; Genmab/Seattle Genetics; GOG Foundation; Gradalis; ImmunoGen; Immunomedics; Incyte; Iovance Biotherapeutics; Iovance Biotherapeutics; Iovance Biotherapeutics; Karyopharm Therapeutics; Laekna Health Care; Merck; Mersana; Myriad Pharmaceuticals; Novocure; Nucana; Oncomed; Oncoquest; Oncosec; Perthera; Pfizer; Puma Biotechnology; Regeneron; Roche/Genentech; Senti Biosciences; Starton Therapeutics; Takeda; Tarveda Therapeutics; TESARO/GSK; Vascular Biogenics; Vavotar Life Sciences; Vigeo Therapeutics

Consulting or Advisory Role - Abbvie; Advaxis; Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Asymmetric Therapeutics; Boston Biomedical; Chemocare; ChemoCare; ChemoID; Clovis Oncology; Deciphera; Eisai; Geistlich Pharma; Genmab/Seattle Genetics; GOG Foundation; Gradalis; ImmunoGen; Immunomedics; Incyte; Iovance Biotherapeutics; Karyopharm Therapeutics; Laekna Health Care; Merck; Mersana; Myriad Pharmaceuticals; Novocure; Nucana; Oncomed; Oncoquest; Oncosec; Perthera; Pfizer; Puma Biotechnology; Regeneron; Roche/Genentech; Senti Biosciences; Sorrento Therapeutics; Sorrento Therapeutics; Takeda; Tarveda Therapeutics; TESARO/GSK; Vascular Biogenics; Vavotar Life Sciences; Vigeo Therapeutics

Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; Merck; Roche/Genentech; TESARO/GSK

Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)